Skip to main content
T
TRAX
(NASDAQ)
First Tracks Biotherapeutics, Inc.
$16.66-- (--)
Loading... - Market loading

First Tracks Biotherapeutics (TRAX) Company Profile

Complete business overview, executive team, trading details, and corporate information.

First Tracks Biotherapeutics, Inc.
TRAXNasdaq Stock MarketHealthcareBiotechnology

About First Tracks Biotherapeutics

First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.

Company Information

CEODaniel Faga
Founded2025
Employees104
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Address
10770 Wateridge Circle, Suite 210 San Diego, California 92121 United States

Corporate Identifiers

ISINUS3371851029

Leadership Team & Key Executives

Daniel R. Faga
Chief Executive Officer, President and Director
Dennis M. Mulroy
Chief Financial Officer
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.
Chief Medical Officer
Benjamin Stone
Chief Business Officer
Eric J. Loumeau
Secretary